Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Hildur Helgadottir, Lars Ny, Gustav J. Ullenhag, Rasmus Mikiver, Karolin Isaksson, Roger Olofsson Bagge

Open source

DOI
10.1016/j.ejca.2025.116201
Published
2026-02
Container
European Journal of Cancer
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.116201,
  title = {Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study},
  author = {Hildur Helgadottir and Lars Ny and Gustav J. Ullenhag and Rasmus Mikiver and Karolin Isaksson and Roger Olofsson Bagge},
  year = {2026},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2025.116201},
  url = {https://doi.org/10.1016/j.ejca.2025.116201}
}

RIS

TY  - JOUR
TI  - Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
AU  - Hildur Helgadottir
AU  - Lars Ny
AU  - Gustav J. Ullenhag
AU  - Rasmus Mikiver
AU  - Karolin Isaksson
AU  - Roger Olofsson Bagge
PY  - 2026
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2025.116201
UR  - https://doi.org/10.1016/j.ejca.2025.116201
ER  - 

APA

Helgadottir, H., Ny, L., Ullenhag, G. J., Mikiver, R., Isaksson, K., & Bagge, R. O. (2026). Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116201

Source records